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Short QT syndrome (SQTS) emerged as a new inherited channelopathy 
characterized by constantly short QT interval (QTc < 360 ms) associated 
with atrial  brillation, syncopal episodes, and/or sudden cardiac death 
in patients with no underlying structural heart disease. It has been 
associated with a gain of function in 3 distinct potassium channels 
(KCNH2, KCNQ1, and KCNJ2) or a loss-of-function of a calcium channel 
Cav1.2. We identi ed a 6-year-old male proband who experienced 
a syncope episode and presented a QTc of 346 ms. In addition, a 
triangular T wave was observed in V2, V3 leads. His 34-year-old mother 
was also symptomatic (QTc: 359 ms), with Ventricular  brillation. The 
grandmother was asymptomatic (QT: 405 ms). After a screen for ion 
channel mutations, we found a variant of CACNA1C, gene encoding 
the α1c of the cardiac L-type calcium channel, leading to c.667G>C 
transition caused a p.A223P substitution of a mammalian highly 
conserved residue. This variant was absent in 312 healthy controls.
Cardiac Ca2+ channels are complexes including α1,β, and α2δ 
subunits allowing the Ca2+ in ux (ICaL) essential for excitation-
contraction coupling. To evaluate the incidence of this substitution 
on Cav1.2 function,α1c,β2a, and α2δ1b rat subunits were transfected 
in HEK-tsA201 cells. The human A223P mutation corresponds to 
A253P in the rat sequence. Whole-cell patch-clamp experiments 
were performed to study the mutation effects on ICaL biophysical 
parameters. A253P Cav1.2 generated a reduced ICaL (-5.48 ± 0.85 Pa/
pF, n = 54) in comparison with WT Cav1.2 (-12.24 ± 1.54 Pa/pF, n = 51). 
The voltage dependence of the Ca2+ current activation did not show 
any change (V1/2act: —11.54±1.15 mV, n=9, versus —12.94±1.03 mV, 
n=19 ; slope: 6.37±0.28 mV versus 6.46±0.27 mV, for mutant and WT 
channels, respectively). Second, we studied WT and mutant Cav1.2 
expression levels. We quanti ed channels expression by Western blot. 
The mutated protein was expressed at the same level as WT-Cav1.2. 
We are currently investigating Cav1.2 addressing to the membrane. 
In conclusion, we have shown that A253P mutation reduces the ICaL 
amplitude but the mechanism behind this loss of function remains to 
be determined.
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Background — Brugada syndrome (BrS) is an inherited arrhythmia 
syndrome with an increased risk of sudden death resulting from 
polymorphic ventricular tachycardia (VT) and/or ventricular 
 brillation (VF) in the absence of gross structural abnormalities. 
Mutations in SCN5A, encoding the pore-forming subunit α of the 
cardiac voltage-gated sodium channel, are identi ed in about 20-30 % 
of probands affected by Brugada syndrome (BrS). SCN5A mutations 
may also lead to progressive cardiac conduction defects (PCCD). The 
causality of SCN5A mutations in PCCD was proven by linkage analysis. 
In contrast, SCN5A mutations in BrS were discovered by a candidate 
gene approach19 and linkage data are still lacking.
The aim of this study was to investigate the association of SCN5A 
mutations and BrS in a group of large genotyped families.
Methods and Results — Families were included if at least 4 family 
members were carriers of the SCN5A mutation identi ed in the 
proband.
Thirteen large families composed by 115 mutation-carriers were 
studied. The signature type I ECG was present in 54 mutation-carriers 
(BrS-ECG+) (47 %). In 5 families, we found 7 individuals affected by BrS, 
but with a negative genotype (mutation-negative BrS-ECG+). Among 
these 7 mutation-negative BrS+ individuals, 3, belonging to 3 different 
families, had a spontaneous type I ECG, while 4 had a type I ECG 
after administration of Na+ channel blockers. EPS was performed in 
5 BrS-ECG non-mutation patients. Ventricular tachyarrhythmias were 
inducible in 3. An ICD was implanted in these 3 patients. Mutation 
carriers (n=115) had, on average, longer PR and QRS intervals than 
non-carriers (n=148) demonstrating that these mutations exerted 
functional effects.
Conclusions — Our results suggest that SCN5A mutations might not 
be suf cient to cause BrS and that genetic background may play 
a powerful role in the pathophysiology of BrS. However, this study 
con rms the role of SCN5A mutations in PCCD.
These  ndings add further complexity to concepts regarding the 
causes of BrS, and are consistent with the emerging notion that the 
pathophysiology of BrS includes various elements beyond mutant 
sodium channels.
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